ResultsIQ

ResultsIQ › Latest results › Fineotex Chemical Limited

Fineotex Chemical Limited Q2 FY27 results deck summary

NSE: FCL · BSE: 533333

Results deck of 14 Nov 2026, summarised by AI from the filing.

Fineotex Q2 FY27 revenue from operations ₹387.65 cr (+181.51%) and PAT ₹44.55 cr (+70.83%), with EBITDA margin down to 15.37% from 22.53%.

Key takeaways

  1. No guidance The deck gives no numeric revenue or margin guidance for FY27; it only lists expansion plans such as capacity in America.
  2. Margins down EBITDA margin fell to 15.37% in Q2 FY27 from 22.53% in Q2 FY26, and gross margin to 29.38% from 38.45%.
  3. Margin risk Cost of raw materials rose to ₹273.78 cr in Q2 FY27 from ₹84.76 cr in Q2 FY26, weighing on profitability.

Original filing on BSE

Fineotex Chemical Limited Q2 FY27 results

As filed: Revenue ₹388 cr (+181% year on year), EBITDA ₹59.6 cr (+99% year on year), PAT ₹44.6 cr (+71% year on year), EBITDA margin 15.4% (−637 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹377 cr (+175% year on year), EBITDA ₹59.1 cr (+137% year on year), PAT ₹48.2 cr (+93% year on year), EBITDA margin 15.7% (−255 bps). Score 96 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin fell 255 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +13.2% in 29 days (Nifty 500: +2.4%).
  • Q4 FY26: Revenue ₹314 cr (+161% year on year), EBITDA ₹43.7 cr (+118% year on year), PAT ₹43.8 cr (+119% year on year), EBITDA margin 13.9% (−274 bps). Score 99 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin fell 274 bps year on year. Tax rate 9%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +54.0% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹184 cr (+46% year on year), EBITDA ₹34.8 cr (+2% year on year), PAT ₹30.1 cr (+8% year on year), EBITDA margin 19.0% (−802 bps). Score 74 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 802 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −8.5% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹138 cr (−5% year on year), EBITDA ₹30.0 cr (−17% year on year), PAT ₹26.0 cr (−19% year on year), EBITDA margin 21.7% (−292 bps). Score 37 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 292 bps year on year. Share price after the results: −5.2% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹137 cr (−4% year on year), EBITDA ₹25.0 cr (−29% year on year), PAT ₹25.0 cr (−14% year on year), EBITDA margin 18.3% (−640 bps). Score 25 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 640 bps year on year. Other income 29% of PBT. Share price after the results: +5.4% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹120 cr (−22% year on year), EBITDA ₹20.0 cr (−49% year on year), PAT ₹20.0 cr (−33% year on year), EBITDA margin 16.7% (−882 bps). Score 1 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 882 bps year on year. Other income 31% of PBT. Revenue fell 5% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹126 cr (−9% year on year), EBITDA ₹34.0 cr (−15% year on year), PAT ₹28.0 cr (−15% year on year), EBITDA margin 27.0% (−200 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 200 bps year on year. Revenue fell 14% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Fineotex Chemical Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.